vs

Side-by-side financial comparison of Sunrise New Energy Co., Ltd. (EPOW) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $22.3M, roughly 1.6× Sunrise New Energy Co., Ltd.). Sunrise New Energy Co., Ltd. runs the higher net margin — -27.1% vs -304.2%, a 277.1% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 0.0%).

Husky Energy Inc. was a Canadian petroleum company that existed from 1938 to 2021. It operated in Western and Atlantic Canada, the United States and the Asia Pacific region, with upstream and downstream business segments. In the 2020 Forbes Global 2000, Husky Energy was ranked as the 1443rd-largest public company in the world.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

EPOW vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.6× larger
RXRX
$35.5M
$22.3M
EPOW
Growing faster (revenue YoY)
RXRX
RXRX
+681.7% gap
RXRX
681.7%
0.0%
EPOW
Higher net margin
EPOW
EPOW
277.1% more per $
EPOW
-27.1%
-304.2%
RXRX

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
EPOW
EPOW
RXRX
RXRX
Revenue
$22.3M
$35.5M
Net Profit
$-6.0M
$-108.1M
Gross Margin
0.1%
59.8%
Operating Margin
-24.3%
-304.8%
Net Margin
-27.1%
-304.2%
Revenue YoY
0.0%
681.7%
Net Profit YoY
-35.7%
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPOW
EPOW
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$22.3M
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$22.3M
$14.4M
Q1 24
$13.8M
Net Profit
EPOW
EPOW
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-6.0M
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-4.5M
$-97.5M
Q1 24
$-91.4M
Gross Margin
EPOW
EPOW
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
0.1%
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
0.1%
36.2%
Q1 24
19.1%
Operating Margin
EPOW
EPOW
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-24.3%
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-24.3%
-697.4%
Q1 24
-698.4%
Net Margin
EPOW
EPOW
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-27.1%
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-20.0%
-676.6%
Q1 24
-662.4%
EPS (diluted)
EPOW
EPOW
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.21
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPOW
EPOW
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$1.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$27.3M
$1.1B
Total Assets
$143.0M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPOW
EPOW
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$1.3M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$15.2M
$474.3M
Q1 24
$296.3M
Total Debt
EPOW
EPOW
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
EPOW
EPOW
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$27.3M
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$-2.8M
$584.4M
Q1 24
$401.2M
Total Assets
EPOW
EPOW
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$143.0M
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$141.6M
$775.9M
Q1 24
$557.8M
Debt / Equity
EPOW
EPOW
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPOW
EPOW
RXRX
RXRX
Operating Cash FlowLast quarter
$-6.9M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPOW
EPOW
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-6.9M
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-6.9M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
EPOW
EPOW
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-7.9M
$-83.4M
Q1 24
$-109.0M
FCF Margin
EPOW
EPOW
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-35.6%
-578.5%
Q1 24
-789.9%
Capex Intensity
EPOW
EPOW
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
4.4%
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons